https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/cannabidiol-trial-shows-reduction-seizures-children-dravet-syndrome/
Cannabidiol trial shows reduction in seizures for children with Dravet syndrome
30 May 2017, 12:58 p.m.
A trial conducted in Europe and the USA has shown that cannabidiol – a drug derived from cannabis but with the psycho-active elements removed – reduces seizures in children with a form of drug resistant epilepsy, known as Dravet syndrome.
The study was led by NIHR GOSH BRC cross cutting theme lead Professor Helen Cross, in collaboration with New York University.
In the trial one hundred and twenty children with Dravet syndrome across Europe and the USA were given two daily doses of cannabidiol orally for fourteen weeks. At the end of the study the average number of severe seizures reduced by nearly 40%. For 5% of patients, seizures stopped completely.
The research, Trial of Cannabidiol for Drug-Resistant seizures in the Dravet Syndrome, was published in the New England Journal of Medicine.
Read the press release.
Building the next generation of paediatric research leaders
From early career clinicians to emerging scientists, the NIHR GOSH Biomedical Research Centre (BRC)’s Academic Training Weekend is shaping the future of paediatric research - bringing together talent, expertise and ambition from across the UK.
Bagri family philanthropy enables UCL study into rare childhood neurological condition treated at GOSH
A generous donation from the Bagri family will underpin a landmark study into gene-editing treatments for Dihydropteridine reductase deficiency (DHPR deficiency), an ultra-rare childhood neurological condition, treated at GOSH
Creating communities and lasting involvement
At GOSH, patient and public involvement and engagement (PPIE) builds lasting relationships and communities that shape research over time.
Junior researchers are crucial to the future of paediatric research
Junior researchers are central to the success and sustainability of paediatric research at GOSH and the University College London Institute of Child Health.